NeuroSense Therapeutics Ltd NRSN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
-
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
-
NeuroSense Announces Pricing of Insider-Led PIPE Financing
-
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
-
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
-
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
-
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
Trading Information
- Previous Close Price
- $0.69
- Day Range
- $0.68–0.73
- 52-Week Range
- $0.63–2.52
- Bid/Ask
- $0.70 / $0.71
- Shares Outstanding
- 36.10M
- Market Cap
- $25.23M
- Volume/Avg
- 20 / 156,591
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.neurosense-tx.com
Valuation
|
Metric
|
NRSN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRSN
|
|---|---|
Quick Ratio | 0.08 |
Current Ratio | 0.31 |
Interest Coverage | — |
Quick Ratio
NRSN
Profitability
|
Metric
|
NRSN
|
|---|---|
Return on Assets (Normalized) | −369.91% |
Return on Equity (Normalized) | −5,348.21% |
Return on Invested Capital (Normalized) | −3,613.65% |
Return on Assets
NRSN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mnwqlwq | Gfpznjl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cjpqgbg | Ynccmwg | $64B | |||
| argenx SE ADR
ARGX
| Qhrmfkdw | Qbll | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gdbtxnggr | Bqgjbq | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Xfrlyjlkq | Jgbqsy | $24B | |||
| BioNTech SE ADR
BNTX
| Lvtqmds | Gxlsn | $23B | |||
| Incyte Corp
INCY
| Kbwgbqn | Hpfvx | $22B | |||
| Moderna Inc
MRNA
| Dcxlwglg | Ryvwt | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wlyxnzb | Shfl | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ngwyrlj | Kyx | $13B |
United States